Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.

Progress in clinical and biological research - 1 Jan 1990

Tong A W, Dalton W S, Tsuruo T, Fay J W, Stone M J

Abstract excerpt

We examined the effectiveness of a previously characterized plasma cell-reactive monoclonal antibody (MoAb), MM4, in eliminating multi-drug resistant (MDR1) multiple myeloma (MM) clonogenic colony-forming cells (CCCs). MDR1 sublines with 6-fold (RPMI8226/DOX6) and 40-fold (RPMI 8226/DOX40) resist...

Topics

Antibodies, Monoclonal
Bone Marrow
Bone Marrow Cells
Cell Survival
Complement System Proteins
Drug Resistance
Humans
Multiple Myeloma
Neoplastic Stem Cells
Phenotype
Tumor Cells, Cultured

Source

Open in PubMed

Identifiers

PMID: 2308979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-2308979-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics